Perikleous Periklis, Waller David A
Department of thoracic surgery, Glenfield Hospital, University Hospitals of Leicester, Leicester, UK.
J Vis Surg. 2017 Jun 22;3:85. doi: 10.21037/jovs.2017.05.05. eCollection 2017.
Parenchymal cancers of lung, breast, gastrointestinal tract and ovaries as well as lymphomas and mesotheliomas are among the most common cancer types causing malignant effusions, though almost all tumour types have been reported to cause a malignant effusion. The prognosis heavily depends on patients' response to systemic therapy however, regardless of the causing pathology and histopathologic form, malignant pleural disease is normally associated with a poor prognosis. To date, there are not sufficient data to allow accurate predictions of survival that would facilitate decision making for managing patients with malignant pleural diseases. Interventions are directed towards drainage of the effusion and, when appropriate, concurrent or subsequent pleurodesis or establishing long-term drainage to prevent re-accumulation. The rate of re-accumulation of the pleural effusion, the patient's prognosis, and the severity of the patient's symptoms should guide the subsequent choice of therapy. In contemporary medicine, not many cancers have managed to generate as intense debates concerning treatment, as malignant pleural mesothelioma. The relative advantages of surgery, radiation, chemotherapy and any combination of the three are continuously reassessed and reconsidered, even though not always based on scientific evidence. The aim of surgery in mesothelioma may be prolongation of life, in addition to palliation of symptoms. Longer recovery periods from more extensive surgical procedures could be justified, in carefully selected patients. Surgical options include: Video assisted thoracoscopic (VATS) pleurodesis, VATS partial pleurectomy (VATS PP)-both parietal and visceral; open pleurectomy decortication (PD)-with an extended option (EPD) and extrapleural pneumonectomy (EPP). Current evidence implies that EPD can be performed reliably in specialised centres with good results, both in terms of mortality and survival; however, no operation has yet been shown to be beneficial in a prospective randomized controlled clinical trial.
肺癌、乳腺癌、胃肠道癌和卵巢癌的实质癌以及淋巴瘤和间皮瘤是导致恶性胸腔积液的最常见癌症类型,不过几乎所有肿瘤类型都有导致恶性胸腔积液的报道。然而,预后很大程度上取决于患者对全身治疗的反应,无论致病病理和组织病理形式如何,恶性胸膜疾病通常预后较差。迄今为止,尚无足够数据能够准确预测生存率,以促进对恶性胸膜疾病患者的管理决策。干预措施旨在引流胸腔积液,适当时进行同期或后续胸膜固定术或建立长期引流以防止积液再积聚。胸腔积液的再积聚率、患者的预后以及患者症状的严重程度应指导后续治疗的选择。在当代医学中,没有多少癌症能像恶性胸膜间皮瘤那样引发如此激烈的治疗争论。手术、放疗、化疗以及三者的任何组合的相对优势都在不断地重新评估和重新考虑,尽管并不总是基于科学证据。间皮瘤手术的目的除了缓解症状外,还可能是延长生命。对于精心挑选的患者,更广泛手术操作带来的更长恢复期可能是合理的。手术选择包括:电视辅助胸腔镜(VATS)胸膜固定术、VATS部分胸膜切除术(VATS PP)——包括壁层和脏层;开放性胸膜剥脱术(PD)——有扩展术式(EPD)和胸膜外全肺切除术(EPP)。目前的证据表明,在专业中心可以可靠地进行EPD,在死亡率和生存率方面都有良好结果;然而,尚无一项手术在前瞻性随机对照临床试验中被证明是有益的。